Relmada Therapeutics Inc RLMD

$3.21 -0.02 (-0.62%)

Valuation

Market cap
344,544,000
Revenue TTM
$0
Net income TTM
$-57,390,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,673,600
Avg volume
1,302,142
Day's range
$3.17 – $3.33
Shares out
106,670,000
Stochastic %K
41%
Beta
0.51
Analysts
Strong Sell
Price target
$10.75

Price

Company profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready f...

Show more

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
786 629 1376
Website
https://www.relmada.com
Address
2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

Latest news

Stocktwits

teaman60 Oct 21, 10:17 PM
$RLMD This is now DOA
0 replies
VictorMason Oct 16, 10:31 PM
$RLMD For Relmada Therapeutics (NASDAQ: RLMD), the figure you want is net cash per share, not cash per share alone. The calculation is: For a biotech company such as RLMD, I would also account for any recent stock offerings, because newly issued shares can materially reduce net cash per share. RLMD net cash per share Based on Relmada's June 30, 2026 quarterly filing Calculated net cash value: approximately $1.92 per share. This is based on reported figures, not a live October balance sheet. RLMD is burning cash to fund clinical development, so the figure will decline over time unless investment income or new financing offsets spending. It also excludes any additional dilution after the reported share count.
0 replies
VictorMason Oct 13, 9:44 PM
$RLMD had the best Phase 2 ever on a depression drug only to blow the phase 3 by a faulty design, didnt even determine the placebo group ever had depression! Paid a bunch of college kids $8,000 to take the placebo for a month and tell them 'how it made them feel' --thinking there might be another payday EVERYONE reported a positive response, even the placebo group had a miraculous response to a depression they never had All they had to do was run a clean phase 3, they paid millions for consultants on the phase 3 the drug worked
0 replies
metalcook Oct 7, 9:12 AM
$RLMD results of phase 2 are based on a monocentric trial (1 site only) in.... israel... I would bet my life on this that it will not repeat the exact efficacy results seen in israel. Lots of examples of fraud there. Fact they bought the drug for pennies on the dollar tells you the entire story.
0 replies
RiskCPremium Oct 5, 10:36 PM
$RLMD Finally made up my mind and pulled the trigger after a long tumultuous journey with Sergio Traversa, the Keyman of Rel-1017. After the acquisition of Trigone's NDV-01 I thought there would be a change in the management and new faces will enter in the BOD, but unfortunately, I see that the organism is manifesting similar morphological patterns once again. Learning to take a small loss is a valuable trait that I am still learning to overcome the resistance of taking the timely loss when my buying hypothesis is invalidated. Departure of Dr. Raj Pruthi as CMO and reading his LinkedIn profile update was the first serious warning for me. I think it was Uy Ear of Mizuho who asked Sergio Traversa - "why did Trigone partner with you", my own personal conclusion led me to take the bets off today. Good luck to you if you are reading this, but first and foremost, please DO your OWN Due Diligence.
0 replies
wetchococo Sep 28, 9:01 PM
$RLMD what’s bothering me is the. 101% yoy increase
0 replies
Momabeat Sep 24, 1:01 PM
$RLMD these insiders have been loading up on this stock!!
1 replies
Momabeat Sep 23, 1:36 PM
$RLMD just bought 10k shares. If insiders can spend over 800k$ each, I can spend a little over 40k$
0 replies